Therapy

Researchers found how ketamine works in depression – but that’s not all

6016 4016 Anna Stelling, PhD

Depression is a widely-spread disease, with over 264 million people being affected worldwide.1 For a subset of patients suffering from major depressive disorder (MDD), administering low doses of the anaesthetic…

read more

Malaria drug brings new hope for glioblastoma patients

4794 3196 Anna Stelling, PhD

Glioblastoma is a very aggressive form of cancer. Even though there is a low number of patients who live longer than 5 years after diagnosis – a statistic that researchers…

read more

Are stem cells in MS ready for prime time?

2300 1535 Peter Stevenson, PhD

Hot topics continued at ECTRIMS 2019 in Stockholm with Joachim Burman (Department of Neurology, Uppsala University Hospital, Sweden), who stepped up to the podium to discuss autologous haematopoietic stem cell transplantation (aHSCT)…

read more

Smartphone-controlled device could revolutionise drug delivery in the brain

3450 2300 Peter Stevenson, PhD

A novel brain implant that can deliver drugs and stimulate brain cells could lead to advanced treatments for Parkinson’s, Alzheimer’s, and other brain disorders, a new study reports. The research comes…

read more
man speaking

Machine-learning algorithm predicts psychosis from speech

3150 2100 Peter Stevenson, PhD

Algorithms designed to find hidden clues within everyday language can predict those at risk of developing psychosis, a new study reports. Using machine learning, researchers from the Department of Psychology…

read more
lab

Establishing sNfL as an MS Biomarker

3300 2200 Carlotta Foletti, PhD

At the ECTRIMS annual congress in October 2018, there was a lot of talk on serum neurofilament light (sNfL) becoming the first blood biomarker predicting neuronal damage caused by neurological…

read more
news

News from the ocrelizumab front

3300 2200 Carlotta Foletti, PhD

In our ongoing coverage of the AAN Annual Meeting in Philadelphia, we are focusing on select posters reporting on studies of ocrelizumab, an intravenous humanised monoclonal antibody that selectively targets…

read more
Doctor

Latest advances in migraine therapy

3682 2200 Carlotta Foletti, PhD

Migraines are the most common type of primary headache disorders, and triptans – serotonin 5-HT1B/1D receptor agonists originally developed as cranial vasoconstrictors – are the backbone of current acute attack…

read more

Could the gut-brain axis have a role in stroke recovery?

3300 2200 Peter Stevenson, PhD

Acute disruption of bacterial populations in the gut after stroke could have a detrimental effect on recovery, according to new research. The role that our microbiome – the microbial environment…

read more

Stem-cell therapy puts the brakes on MS

2850 1900 Peter Stevenson, PhD

New data reveal the power of stem-cell transplantation in slowing or even halting disease progression in patients with RRMS, thereby reinvigorating further exploration of cellular treatments in MS. The findings…

read more
Brainwork is supported by unrestricted grants from: